73 related articles for article (PubMed ID: 26143525)
1. Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs.
Di Giacopo R; Cianetti L; Caputo V; La Torraca I; Piemonte F; Ciolfi A; Petrucci S; Carta C; Mariotti P; Leuzzi V; Valente EM; D'Amico A; Bentivoglio A; Bertini E; Tartaglia M; Zampino G
J Neurol Sci; 2015 Sep; 356(1-2):65-71. PubMed ID: 26143525
[TBL] [Abstract][Full Text] [Related]
2. Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America.
Kohan R; Carabelos MN; Xin W; Sims K; Guelbert N; Cismondi IA; Pons P; Alonso GI; Troncoso M; Witting S; Pearce DA; Dodelson de Kremer R; Oller-Ramírez AM; Noher de Halac I
Gene; 2013 Mar; 516(1):114-21. PubMed ID: 23266810
[TBL] [Abstract][Full Text] [Related]
3. CLN2 disease resulting from a novel homozygous deep intronic splice variant in TPP1 discovered using long-read sequencing.
Steigerwald C; Borsuk J; Pappas J; Galey M; Scott A; Devaney JM; Miller DE; Abreu NJ
Mol Genet Metab; 2023 Dec; 140(4):107713. PubMed ID: 37922835
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of tripeptidyl-peptidase 1 by 3-hydroxy-(2,2)-dimethyl butyrate, a brain endogenous ligand of PPARα: Implications for late-infantile Batten disease therapy.
Chakrabarti S; Chandra S; Roy A; Dasarathi S; Kundu M; Pahan K
Neurobiol Dis; 2019 Jul; 127():362-373. PubMed ID: 30928643
[TBL] [Abstract][Full Text] [Related]
5. Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1.
Collier AM; Nemtsova Y; Kuber N; Banach-Petrosky W; Modak A; Sleat DE; Nanda V; Lobel P
Biochem J; 2020 Feb; 477(3):727-745. PubMed ID: 31957806
[TBL] [Abstract][Full Text] [Related]
6. A computational approach to analyzing the functional and structural impacts of Tripeptidyl-Peptidase 1 missense mutations in neuronal ceroid lipofuscinosis.
K P; Madhana PN; Eswaramoorthy R; Ramasamy M
Metab Brain Dis; 2024 Apr; 39(4):545-558. PubMed ID: 38185715
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure and autoactivation pathway of the precursor form of human tripeptidyl-peptidase 1, the enzyme deficient in late infantile ceroid lipofuscinosis.
Guhaniyogi J; Sohar I; Das K; Stock AM; Lobel P
J Biol Chem; 2009 Feb; 284(6):3985-97. PubMed ID: 19038967
[TBL] [Abstract][Full Text] [Related]
8. A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease.
Lourenço CM; Sallum JMF; Pereira AM; Girotto PN; Kok F; Vilela DRF; Barron E; Pessoa A; Oliveira BM
Arq Neuropsiquiatr; 2024 May; 82(5):1-8. PubMed ID: 38763144
[TBL] [Abstract][Full Text] [Related]
9. Moving towards effective therapeutic strategies for Neuronal Ceroid Lipofuscinosis.
Geraets RD; Koh Sy; Hastings ML; Kielian T; Pearce DA; Weimer JM
Orphanet J Rare Dis; 2016 Apr; 11():40. PubMed ID: 27083890
[TBL] [Abstract][Full Text] [Related]
10. TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease.
Haney MJ; Klyachko NL; Harrison EB; Zhao Y; Kabanov AV; Batrakova EV
Adv Healthc Mater; 2019 Jun; 8(11):e1801271. PubMed ID: 30997751
[TBL] [Abstract][Full Text] [Related]
11. A current view of mitochondria damage and the diversity of lipopigment inclusions in neuronal ceroid lipofuscinose type 2 from rectal biopsy.
Felczak P; Kuźniar-Pałka A; Ługowska A; Stawicka E; Tarka S; Mierzewska H
Folia Neuropathol; 2024; 62(1):21-31. PubMed ID: 38741434
[TBL] [Abstract][Full Text] [Related]
12. Extracellular Vesicles Released by Genetically Modified Macrophages Activate Autophagy and Produce Potent Neuroprotection in Mouse Model of Lysosomal Storage Disorder, Batten Disease.
El-Hage N; Haney MJ; Zhao Y; Rodriguez M; Wu Z; Liu M; Swain CJ; Yuan H; Batrakova EV
Cells; 2023 May; 12(11):. PubMed ID: 37296618
[TBL] [Abstract][Full Text] [Related]
13. A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.
Swier VJ; White KA; Johnson TB; Sieren JC; Johnson HJ; Knoernschild K; Wang X; Rohret FA; Rogers CS; Pearce DA; Brudvig JJ; Weimer JM
Neurotherapeutics; 2022 Oct; 19(6):1905-1919. PubMed ID: 36100791
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Molecular Characteristics of Neuronal Ceroid Lipofuscinosis in Saudi Arabia.
Saleh MM; Hamhom AM; Al-Otaibi A; AlGhamdi M; Housawi Y; Aljadhai YI; Alameer S; Almannai M; Jad LA; Alwadei AH; Tabassum S; Alsaman A; AlAsmari A; Al Mutairi F; Althiyab H; Bashiri FA; AlHumaidi S; Alfadhel M; Mink JW; AlHashim A; Faqeih EA;
Pediatr Neurol; 2024 Jun; 155():149-155. PubMed ID: 38653183
[TBL] [Abstract][Full Text] [Related]
15. Acidified drinking water improves motor function, prevents tremors and changes disease trajectory in Cln2
Kovács AD; Gonzalez Hernandez JL; Pearce DA
Sci Rep; 2023 Nov; 13(1):19229. PubMed ID: 37932327
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of cerliponase alfa in children with neuronal ceroid lipofuscinosis type 2 (CLN2 disease): an open-label extension study.
Schulz A; Specchio N; de Los Reyes E; Gissen P; Nickel M; Trivisano M; Aylward SC; Chakrapani A; Schwering C; Wibbeler E; Westermann LM; Ballon DJ; Dyke JP; Cherukuri A; Bondade S; Slasor P; Cohen Pfeffer J
Lancet Neurol; 2024 Jan; 23(1):60-70. PubMed ID: 38101904
[TBL] [Abstract][Full Text] [Related]
17. Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa.
Guelbert N; Espitia Segura OM; Amoretti C; Arteaga Arteaga A; Atanacio NG; Bazan Natacha S; Carvalho EDF; Carvalho de Andrade MDF; Denzler IM; Durand C; Ribeiro E; Giugni JC; González G; González Moron D; Guelbert G; Hernández Rodriguez ZJ; Embiruçu Emilia K; Kauffman MA; Mancilla NI; Marcon L; Marques Pereira A; Fischinger Moura de Souza C; Muñoz VA; Naranjo Flórez RA; Pessoa AL; Ruiz MV; Solano Villareal ML; Spécola N; Tavera LM; Tello J; Troncoso Schifferli M; Ugrina S; Vaccarezza MM; Vergara D; Villanueva MM
Mol Genet Metab Rep; 2024 Mar; 38():101060. PubMed ID: 38469103
[TBL] [Abstract][Full Text] [Related]
18. Case Report: Intraventricular Cerliponase Alfa Treatment in a Patient with Advanced Neuronal Ceroid Lipofuscinosis Type 2.
Nakashima S; Hamada M; Kimura T; Tanifuji S; Takahashi A; Yashita D; Kakimoto Y; Matsukawa T; Ishiura H; Toda T
Intern Med; 2023 Nov; ():. PubMed ID: 37926545
[TBL] [Abstract][Full Text] [Related]
19. Cerliponase alfa and neuronal ceroid lipofuscinosis type 2: long-term outcomes and lessons for future research.
Boustany RM
Lancet Neurol; 2024 Jan; 23(1):5-7. PubMed ID: 38101903
[No Abstract] [Full Text] [Related]
20.
Vafaei N; Mohebbi A; Rezaei Z; Heidari M; Hosseinpour S; Dehnavi AZ; Ghamari A; Salehipour M; Rabbani A; Mahdieh N; Ashrafi MR
Mol Syndromol; 2024 Feb; 15(1):30-36. PubMed ID: 38357261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
